Ranbaxy has acquired 13 dermatology brands in US from Bristol-Myers Squibb. The company paid $26 million for the brands which generated revenues of $15 million.
Malvinder Singh, CEO added that Ranbaxy’s branded business strategy in the US will continue to happen in a phased manner. The company is looking at more profit-making brands in the US and the focus is on adding more products in dermatology. Ranbaxy may see 10% growth in the dermatology segment in the US.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment